Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: A meta-analysis

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 735-741

  Li, Chun Yu ^a   Yuan, Peng ^a   Lin, Shu Sen ^a   Song, Cheng Fei ^a   Guan, Wei Yu ^a   Yuan, Lu ^a   Lai, Rong Bin ^a   Gao, Ying ^a   Wang, Yan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Matrix metalloproteinase 9; Meta analysis; Survival

Indexed keywords

GELATINASE B; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; CASE CONTROL STUDY; COLORECTAL TUMOR; META ANALYSIS; METABOLISM; MORTALITY; PROGNOSIS; SURVIVAL RATE;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 9; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877107591     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0601-2     Document Type: Article

References (32)

1. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.
2. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-99.
3. Zhou Y, Li G, Wu J, Zhang Z, Wu Z, Fan P, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010;31:549-58.
4. Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21:645-53.
5. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221-33.
6. Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2012;19:318-25.
7. Langers AM, Verspaget HW, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, et al. Mmp-2 and mmp-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. Br J Cancer. 2012;106:1495-8.
8. Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, et al. Gelatinase b expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol. 2008;31:55-63.
9. Langers AM, Sier CF, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, et al. Mmp-2 geno-phenotype is prognostic for colorectal cancer survival, whereas mmp-9 is not. Br J Cancer. 2008;98:1820-3.
10. Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, Mizobe T, et al. The mmp-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol. 2006;57:577-83.
11. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, et al. Mmp-9 (gelatinase b) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 2010;28:38-43.
12. Cho YR, Kwon HC, Suh SH, Lee JH, Kim SH, Choi HJ, et al. Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer. Cancer Res Treat. 2005;37:354-9.
13. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with mmp-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res. 2004;10:5572-9.
14. Jensen SA, Vainer B, Bartels A, Brunner N, Sorensen JB. Expression of matrix metalloproteinase 9 (mmp-9) and tissue inhibitor of metalloproteinases 1 (timp-1) by colorectal cancer cells and adjacent stroma cells-associations with histopathology and patients outcome. Eur J Cancer. 2010;46:3233-42.
15. Cho YB, Lee WY, Song SY, Shin HJ, Yun SH, Chun HK. Matrix metalloproteinase-9 activity is associated with poor prognosis in t3-t4 node-negative colorectal cancer. Hum Pathol. 2007;38:1603-10.
16. Zhang Y, Guan XY, Dong B, Zhao M, Wu JH, Tian XY, Hao CY. Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features. J Cancer Res Clin Oncol 2012
17. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14:3133-40.
18. Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage ii colorectal carcinoma. J Gastrointest Cancer. 2009;40:91-7.
19. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-34.
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
24. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030-47.
25. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507.
26. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823-32.
27. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529-36.
28. Koskensalo S, Louhimo J, Nordling S, Hagstrom J, Haglund C. Mmp-7 as a prognostic marker in colorectal cancer. Tumour Biol. 2011;32:259-64.
29. Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol. 2010;31:651-8.
30. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. Prognostic significance of transforming growth factor beta (TGF-beta) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biol. 2012;33:1005-14.
31. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004;16:558-64.
32. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617-29.